Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preterm Immune Development and Vaccine Response Study
NL-OMON56341Recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Dec 2022
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label trial of DTaP5-HB-IPV-Hib vaccine, pneumococcal conjugate vaccine and tdap vaccine in Preventable infectious diseases (VPD), diphtheria, Tetanus and 5 more (2 arms), sponsored by Maastricht University Medical Center+. Primary endpoint: Protective IgG response after primary hexavalent vaccination in preterm infants. Started Dec 2022; status: recruiting.
02
Drugs
DTaP5-HB-IPV-Hib vaccinepneumococcal conjugate vaccinetdap vaccine
03
Conditions
Preventable infectious diseases (VPD)diphtheriaTetanuspertussispoliomyelitis
Beyond the preview
Go deeper on NL-OMON56341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56341.